Baclofen in the Treatment of Spasticity
Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlle...
Gespeichert in:
| Veröffentlicht in: | BMJ 1971-10, Vol.4 (5778), p.15-17 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 5778 |
| container_start_page | 15 |
| container_title | BMJ |
| container_volume | 4 |
| creator | Hudgson, P. Weightman, D. |
| description | Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective. |
| doi_str_mv | 10.1136/bmj.4.5778.15 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1799146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>25416062</jstor_id><sourcerecordid>25416062</sourcerecordid><originalsourceid>FETCH-LOGICAL-b503t-74335b9b9ef555e2bd9c530a09e889f439495b0408471b5583c9edfaf9b1a94a3</originalsourceid><addsrcrecordid>eNp9kEFPwjAYhhujQYIcPZos8aCXYbu263oxURTUIB5ED16adnSyCRu2xci_twtk6MVT07xPvu_5XgCOEewhhOMLtSh6pEcZS3qI7oE2InES0gTjfdCGELIQEcIOQdfawn8jzBIekxZoEY6TiOA2OLuW6bzKdBnkZeBmOpgYLd1Cly6osuB5Ka3L09ytj8BBJudWd7dvB7wMbif9u3D0NLzvX41CRSF2ISMYU8UV1xmlVEdqylOKoYRcJwnPCOaEUwUJTAhDinrTlOtpJjOukORE4g643MxdrtRCT1MvYuRcLE2-kGYtKpmLv0mZz8R79SUQ49xf7wecbgeY6nOlrRNFtTKld_YIi-vWKPVUuKFSU1lrdNZsQFDUjPDNCiLqZgWq-ZPfWg297XGXF9ZVpokjSlAM42i3L7dOfze5NB8iZphRMX7ti4eb8YC-PcZi6PnzDV9r_K_2A49KmGM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776113655</pqid></control><display><type>article</type><title>Baclofen in the Treatment of Spasticity</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>PubMed Central</source><creator>Hudgson, P. ; Weightman, D.</creator><creatorcontrib>Hudgson, P. ; Weightman, D.</creatorcontrib><description>Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.4.5778.15</identifier><identifier>PMID: 4938243</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adult ; Aminobutyrates - adverse effects ; Aminobutyrates - therapeutic use ; Clinical Trials as Topic ; Electromyography ; Experimentation ; Female ; Humans ; Injections, Intravenous ; Intravenous injections ; Lower extremity ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - complications ; Muscle Spasticity - drug therapy ; Nausea - chemically induced ; Papers and Originals ; Paralysis - etiology ; Placebos ; Pretreatment ; Side effects ; Spinal cord diseases ; Spinal Cord Diseases - complications ; Standard error ; Statistical results ; Vertigo - chemically induced</subject><ispartof>BMJ, 1971-10, Vol.4 (5778), p.15-17</ispartof><rights>Copyright 1971 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Oct 2, 1971</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b503t-74335b9b9ef555e2bd9c530a09e889f439495b0408471b5583c9edfaf9b1a94a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/25416062$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/25416062$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,803,885,27924,27925,53791,53793,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4938243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hudgson, P.</creatorcontrib><creatorcontrib>Weightman, D.</creatorcontrib><title>Baclofen in the Treatment of Spasticity</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective.</description><subject>Adult</subject><subject>Aminobutyrates - adverse effects</subject><subject>Aminobutyrates - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Electromyography</subject><subject>Experimentation</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Intravenous injections</subject><subject>Lower extremity</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - complications</subject><subject>Muscle Spasticity - drug therapy</subject><subject>Nausea - chemically induced</subject><subject>Papers and Originals</subject><subject>Paralysis - etiology</subject><subject>Placebos</subject><subject>Pretreatment</subject><subject>Side effects</subject><subject>Spinal cord diseases</subject><subject>Spinal Cord Diseases - complications</subject><subject>Standard error</subject><subject>Statistical results</subject><subject>Vertigo - chemically induced</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1971</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEFPwjAYhhujQYIcPZos8aCXYbu263oxURTUIB5ED16adnSyCRu2xci_twtk6MVT07xPvu_5XgCOEewhhOMLtSh6pEcZS3qI7oE2InES0gTjfdCGELIQEcIOQdfawn8jzBIekxZoEY6TiOA2OLuW6bzKdBnkZeBmOpgYLd1Cly6osuB5Ka3L09ytj8BBJudWd7dvB7wMbif9u3D0NLzvX41CRSF2ISMYU8UV1xmlVEdqylOKoYRcJwnPCOaEUwUJTAhDinrTlOtpJjOukORE4g643MxdrtRCT1MvYuRcLE2-kGYtKpmLv0mZz8R79SUQ49xf7wecbgeY6nOlrRNFtTKld_YIi-vWKPVUuKFSU1lrdNZsQFDUjPDNCiLqZgWq-ZPfWg297XGXF9ZVpokjSlAM42i3L7dOfze5NB8iZphRMX7ti4eb8YC-PcZi6PnzDV9r_K_2A49KmGM</recordid><startdate>19711002</startdate><enddate>19711002</enddate><creator>Hudgson, P.</creator><creator>Weightman, D.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>19711002</creationdate><title>Baclofen in the Treatment of Spasticity</title><author>Hudgson, P. ; Weightman, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b503t-74335b9b9ef555e2bd9c530a09e889f439495b0408471b5583c9edfaf9b1a94a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1971</creationdate><topic>Adult</topic><topic>Aminobutyrates - adverse effects</topic><topic>Aminobutyrates - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Electromyography</topic><topic>Experimentation</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Intravenous injections</topic><topic>Lower extremity</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - complications</topic><topic>Muscle Spasticity - drug therapy</topic><topic>Nausea - chemically induced</topic><topic>Papers and Originals</topic><topic>Paralysis - etiology</topic><topic>Placebos</topic><topic>Pretreatment</topic><topic>Side effects</topic><topic>Spinal cord diseases</topic><topic>Spinal Cord Diseases - complications</topic><topic>Standard error</topic><topic>Statistical results</topic><topic>Vertigo - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hudgson, P.</creatorcontrib><creatorcontrib>Weightman, D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hudgson, P.</au><au>Weightman, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baclofen in the Treatment of Spasticity</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1971-10-02</date><risdate>1971</risdate><volume>4</volume><issue>5778</issue><spage>15</spage><epage>17</epage><pages>15-17</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>4938243</pmid><doi>10.1136/bmj.4.5778.15</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1447 |
| ispartof | BMJ, 1971-10, Vol.4 (5778), p.15-17 |
| issn | 0007-1447 0959-8138 1468-5833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1799146 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; PubMed Central |
| subjects | Adult Aminobutyrates - adverse effects Aminobutyrates - therapeutic use Clinical Trials as Topic Electromyography Experimentation Female Humans Injections, Intravenous Intravenous injections Lower extremity Male Middle Aged Multiple sclerosis Multiple Sclerosis - complications Muscle Spasticity - drug therapy Nausea - chemically induced Papers and Originals Paralysis - etiology Placebos Pretreatment Side effects Spinal cord diseases Spinal Cord Diseases - complications Standard error Statistical results Vertigo - chemically induced |
| title | Baclofen in the Treatment of Spasticity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A21%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baclofen%20in%20the%20Treatment%20of%20Spasticity&rft.jtitle=BMJ&rft.au=Hudgson,%20P.&rft.date=1971-10-02&rft.volume=4&rft.issue=5778&rft.spage=15&rft.epage=17&rft.pages=15-17&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.4.5778.15&rft_dat=%3Cjstor_pubme%3E25416062%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776113655&rft_id=info:pmid/4938243&rft_jstor_id=25416062&rfr_iscdi=true |